KEFTAB
LOE ApproachingNDAORALTABLET
Approved
Oct 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFTAB is an oral tablet small-molecule NDA approved in 1987 by Eli Lilly and Company. The specific mechanism of action and indications are not publicly disclosed in available data. This legacy product represents a mature therapeutic asset in the oral tablet market.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team size and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest minimal active hiring for KEFTAB roles, indicating a stable but non-growth environment. Career opportunities focus on managed decline and generic transition strategy rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on KEFTAB at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.